Clinical trial · Observational
Burden of Disease in Myasthenia Gravis
Questionnaire Survey on the Systematic Recording and Characterization of Quality of Life Limitations in Myasthenia Gravis
NCT03979521CI-TRIAL-00055774Mya-BoDcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Questionnaire-based survey addressed to german patients with the chronic autoimmune muscle disease called myasthenia gravis regarding quality of life, socioeconomic impact, social support, course of disease, complications of therapy and psychological comorbidities.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Questionnaire for self-completion by patients containing questions about general information, information on myasthenia, information socioeconomic situation
- timeFrame
- directly after inclusion in the study
- measure
- Hospital Anxiety and Depression Scale (HADS)
- timeFrame
- directly after inclusion in the study
- description
- Questionnaire for self-completion by patients to determine the levels of anxiety and depression
- measure
- Mya Quality of Life 15 (Mya QoL15)
- timeFrame
- directly after inclusion in the study
- description
- Questionnaire for self-completion by patients for use as a measure of health outcome
- measure
- Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF36)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with Myasthenia Gravis * Age ≥18 years Exclusion Criteria: * none
References
Publications (4)
- RESULTLehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, Stascheit F, Krause M, Hoffmann S, Meisel A. Burden of disease in myasthenia gravis: taking the patient's perspective. J Neurol. 2022 Jun;269(6):3050-3063. doi: 10.1007/s00415-021-10891-1. Epub 2021 Nov 20. PMID 34800167
- DERIVEDLehnerer S, Stegherr R, Grittner U, Stein M, Gerischer L, Stascheit F, Herdick M, Doksani P, Meisel A, Hoffmann S. The burden of disease in seronegative myasthenia gravis: a patient-centered perspective. Front Immunol. 2025 Apr 8;16:1555075. doi: 10.3389/fimmu.2025.1555075. eCollection 2025. PMID 40264778
- DERIVEDLehnerer S, Herdick M, Mevius A, Grittner U, Gansel P, Joeres L, Biskup J, Meisel A. The economic burden of Myasthenia gravis from the patient s perspective and reflected in German claims data. Sci Rep. 2025 Feb 25;15(1):6687. doi: 10.1038/s41598-025-91372-7. PMID 39994434
- DERIVEDStein M, Grittner U, Stegherr R, Gerischer L, Stascheit F, Hoffmann S, Herdick M, Legg D, Marbin D, Meisel A, Lehnerer S. The burden of myasthenia gravis - highlighting the impact on family planning and the role of social support. Front Neurol. 2023 Dec 14;14:1307627. doi: 10.3389/fneur.2023.1307627. eCollection 2023. PMID 38162439